文献速递头颈PETCT

复发或转移性鼻咽癌中18F-氟脱氧葡萄糖正电子发射断层显像/计算机断层显像的肿瘤与脂肪组织摄取预测免疫治疗反应

Tumour and adipose tissue uptake on 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) predict immunotherapy response in recurrent or metastatic nasopharyngeal carcinoma.
PubMed 文献 · Clin Radiol · 2025-05-14

该回顾性研究纳入120例接受PD-1抑制剂治疗的复发或转移性鼻咽癌患者,测量肿瘤及皮下/内脏脂肪组织的18F-FDG摄取参数。临床获益组原发肿瘤MTV、TLG及内脏脂肪SUVmax显著低于无临床获益组。肺转移和较高原发肿瘤负荷是PFS独立预测因素,仅原发肿瘤负荷是OS独立预测因素,SUVmax-VAT可能是有前景的免疫治疗反应预测指标。

要点

  • 原发肿瘤MTV、TLG及内脏脂肪SUVmax在临床获益组显著低于无临床获益组。
  • 肺转移和较高原发肿瘤负荷是PFS独立预测因素,仅原发肿瘤负荷是OS独立预测因素。
  • SUVmax-VAT可能是有前景的免疫治疗反应预测指标。

核心结论

  • 较高的原发肿瘤负荷与接受免疫治疗的鼻咽癌患者不良预后相关,SUVmax-VAT可能是有前景的免疫治疗反应预测指标。

研究设计与样本

  • 回顾性纳入120例接受PD-1抑制剂治疗的复发或转移性鼻咽癌患者,记录所有恶性病灶的SUVmax、MTV和TLG,并测量皮下和内脏脂肪组织的SUVmax和SUVmean,以免疫治疗6个月内肿瘤进展、死亡或更换方案定义为无临床获益组,其余为临床获益组,主要终点为PFS和OS。

关键影像表现/征象

  • 临床获益组原发肿瘤MTV中位数15.8 vs 无临床获益组48.1(P=0.006)。
  • 临床获益组原发肿瘤TLG中位数88.7 vs 无临床获益组275.6(P=0.008)。
  • 临床获益组内脏脂肪SUVmax中位数0.63 vs 无临床获益组0.77(P=0.047)。
  • 无临床获益组T4期比例71.4% vs 临床获益组41.3%。
  • 无临床获益组肺转移比例42.9% vs 临床获益组21.7%。

诊断标准与关键数值

  • 多因素分析显示肺转移是PFS独立预测因素(P=0.002,HR=2.204,95%CI:1.323-3.669)。
  • 多因素分析显示较高原发肿瘤负荷是PFS独立预测因素(P<0.001,HR=3.379,95%CI:1.768-6.460)。
  • 多因素分析显示仅较高原发肿瘤负荷是OS独立预测因素(P=0.027,HR=2.513,95%CI:1.108-5.698)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: This study evaluated the prognostic value of 18F-Fluorodeoxyglucose (18F-FDG) uptake in tumour and adipose tissue in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients treated with immunotherapy.

MATERIALS AND METHODS: We retrospectively included 120 patients with R/M NPC treated with PD-1 inhibitors. Maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) of all malignant lesions were recorded. Additionally, SUVmax and SUVmean were measured for subcutaneous and visceral adipose tissue (SAT and VAT). The study classified patients who, within six months of immunotherapy, either experienced tumour progression, died, or changed treatment regimens as the nonclinical benefit (non-CB) group, and others as the CB group. The primary endpoints were progression-free survival (PFS) and overall survival (OS).

RESULTS: The CB group had significantly lower primary tumour MTV (PT-MTV) (median, 15.8 vs 48.1, P=0.006), PT-TLG (median, 88.7 vs 275.6, P=0.008) and SUVmax-VAT (median, 0.63 vs 0.77, P=0.047) than non-CB group. More T4 stages (71.4% vs. 41.3%) and lung metastases (42.9% vs 21.7%) were observed in the non-CB group compared to the CB group. Multivariate analysis indicated lung metastases (P=0.002, hazard ratio [HR] = 2.204, 95% confidence interval [CI]: 1.323-3.669) and higher primary tumour burden (P<0.001, HR= 3.379, 95% CI: 1.768-6.460) as independent PFS predictors. Only higher primary tumour burden (P=0.027, HR=2.513, 95% CI: 1.108-5.698) was an independent OS predictor.

CONCLUSION: Our study indicates that higher primary tumour burden is associated with poor prognosis for NPC patients undergoing immunotherapy. SUVmax-VAT may be a promising predictor for immunotherapy response.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Bao J, Xiong M, Zheng M, et al. Tumour and adipose tissue uptake on 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) predict immunotherapy response in recurrent or metastatic nasopharyngeal carcinoma. Clin Radiol. 2025. PMID: 40527159. doi:10.1016/j.crad.2025.106959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。